Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. Cohen EEW, et al. Among authors: bifulco cb. J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5. J Immunother Cancer. 2019. PMID: 31307547 Free PMC article. Clinical Trial.
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, Patel AA, Cheng AC, Watters AL, Bifulco C, Morris G, Rushforth L, Nemeth S, Urba WJ, Gough M, Bell RB. Leidner R, et al. J Immunother Cancer. 2021 May;9(5):e002485. doi: 10.1136/jitc-2021-002485. J Immunother Cancer. 2021. PMID: 33963014 Free PMC article. Clinical Trial.
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Rajamanickam V, Chang SC, Koguchi Y, Bifulco CB, Bernard B, Leidner RS, Curti BD, Fox BA, Urba WJ, Bell RB, Weinberg AD. Duhen R, et al. Among authors: bifulco cb. Nat Commun. 2021 Feb 16;12(1):1047. doi: 10.1038/s41467-021-21383-1. Nat Commun. 2021. PMID: 33594075 Free PMC article. Clinical Trial.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).
Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I. Ascierto PA, et al. J Immunother Cancer. 2019 Nov 29;7(1):332. doi: 10.1186/s40425-019-0798-3. J Immunother Cancer. 2019. PMID: 31783779 Free PMC article.
Multiparametric immune profiling in HPV- oral squamous cell cancer.
Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, Cheng A, Bui T, Leidner R, Urba WJ, Johnson K, Hoyt C, Bifulco CB, Bukur J, Wickenhauser C, Seliger B, Fox BA. Feng Z, et al. Among authors: bifulco cb. JCI Insight. 2017 Jul 20;2(14):e93652. doi: 10.1172/jci.insight.93652. eCollection 2017 Jul 20. JCI Insight. 2017. PMID: 28724788 Free PMC article.
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB; Society for Immunotherapy of Cancer (SITC) Pathology Task Force.. Taube JM, et al. Among authors: bifulco cb. J Immunother Cancer. 2020 May;8(1):e000155. doi: 10.1136/jitc-2019-000155. J Immunother Cancer. 2020. PMID: 32414858 Free PMC article.
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021.
Ascierto PA, Avallone A, Bhardwaj N, Bifulco C, Bracarda S, Brody JD, Buonaguro L, Demaria S, Emens LA, Ferris RL, Galon J, Khleif SN, Klebanoff CA, Laskowski T, Melero I, Paulos CM, Pignata S, Ruella M, Svane IM, Taube JM, Fox BA, Hwu P, Puzanov I. Ascierto PA, et al. J Transl Med. 2022 Jun 7;20(1):257. doi: 10.1186/s12967-022-03471-y. J Transl Med. 2022. PMID: 35672823 Free PMC article.
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.
Ascierto PA, Bifulco C, Galon J, Garbe C, Khleif SN, McQuade J, Odunsi K, Okada H, Paulos CM, Quezada SA, Tawbi HA, Timmerman J, Trinchieri G, Butterfield LH, Puzanov I. Ascierto PA, et al. J Immunother Cancer. 2020 Aug;8(2):e000921. doi: 10.1136/jitc-2020-000921. J Immunother Cancer. 2020. PMID: 32843491 Free PMC article.
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy).
Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Ascierto PA, et al. J Transl Med. 2021 Jun 2;19(1):238. doi: 10.1186/s12967-021-02895-2. J Transl Med. 2021. PMID: 34078406 Free PMC article.
82 results